US FDA News: FDA Statement on the FDA’s ongoing investigation into valsartan and ARB class impurities and the agency’s steps to address the root causes of the safety issues

FDA describes the ongoing investigation into the ARB class impurities and agency’s steps to address the root causes of the safety issues
Read more: FDA Statement on the FDA’s ongoing investigation into valsartan and ARB class impurities and the agency’s steps to address the root causes of the safety issues